Results 81 to 90 of about 606,321 (264)

COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study

open access: yesInteractive Journal of Medical Research
BackgroundObservation of COVID-19 rebound after nirmatrelvir plus ritonavir (NPR) has driven important questions surrounding one of the only direct-acting antiviral treatments for COVID-19.
Jacqueline K Kueper   +11 more
doaj   +1 more source

RPLP2 Mediates the Beneficial Effects of Exercise on Stress Resistance Through Muscle–Brain Communication

open access: yesAdvanced Science, EarlyView.
A novel exercise‐inducible myokine acidic ribosomal protein P2 (RPLP2), initially identified from human trials, is presented here, whose circulating levels negatively correlate with clinical anxiety severity. Muscle‐derived RPLP2 enhances hippocampal ribosomal assembly and adult neurogenesis to rescue stress‐induced anxiety deficits.
Peiyu Luo   +18 more
wiley   +1 more source

Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion.

open access: yesPLoS Pathogens
Most people living with HIV-1 experience rapid viral rebound once antiretroviral therapy is interrupted; however, a small fraction remain in viral remission for an extended duration.
Tin Phan   +9 more
doaj   +1 more source

Determinants of post-treatment rebound setpoint viral load.

open access: yes, 2023
We analysed animals from the three cohorts to understand factors associated with the post-rebound setpoint viral level. Viral load at treatment (A) and peak viral load before treatment (B) where poorly predictive of post-rebound setpoint viral load when ...
Christine M. Fennessey (10777108)   +10 more
core   +1 more source

Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS‐CoV‐2 Omicron Variants

open access: yesAdvanced Science, EarlyView.
Engineering of the 148‐germline (148‐GL) antibody reveals a roadmap for overcoming SARS‐CoV‐2 viral escape. By introducing four specific somatic hypermutations, the resulting 148‐M4 variant restores potent neutralization against Omicron BA.1 and BA.4/5.
Huibin Lv   +14 more
wiley   +1 more source

Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed

open access: yesJHEP Reports, 2020
Background & Aims: Nucleos(t)ide analogues (NUCs) effectively suppress serum HBV DNA. Previously, we have identified 21 patients with undetectable covalently closed circular DNA (cccDNA) upon long-term NUC therapy.
Ching-Lung Lai   +5 more
doaj   +1 more source

Energy Elasticities and the Rebound Effect: A Comprehensive Empirical Analysis [PDF]

open access: yes, 2016
In diesem Forschungsprojekt werden aktuelle Preis- und Einkommenselastizitäten für Energie und andere Produktionsfaktoren bzw. Konsumgütergruppen in der Schweiz geschätzt. Im Weiteren wird der Rebound-Effekt für den privaten Transport untersucht.
Müller, Daniel   +2 more
core  

Targeted Degradation of STING by a Neutrophil Membrane‐Coated Nanoplatform Suppresses Microglial Pyroptosis After Subarachnoid Hemorrhage

open access: yesAdvanced Science, EarlyView.
MG1@NM‐Px serves as a microglia‐targeted STING‐degrading nanoplatform for subarachnoid hemorrhage. Following systemic administration, it crosses the blood–brain barrier and accumulates in activated microglia. STP1‐mediated STING ubiquitination and degradation suppress MAPK/inflammasome signaling, GSDME‐mediated pyroptosis, and IL‐1β release, revealing ...
Ruotian Zhang   +13 more
wiley   +1 more source

Dual Blockade of LILRB1 and LILRB2 Enhances Antiviral Immune Responses in SIV Infection

open access: yesAdvanced Science, EarlyView.
Dual LILRB1/B2 blockade with mac20G10 reshapes myeloid activation during acute SIV infection by targeting LILRB1 and LILRB2 on myeloid cells. This treatment enhances CD80 expression on selected myeloid subsets and increases plasma IFN‐λ, IL‐8, and IL‐1RA.
Florian Meurisse   +20 more
wiley   +1 more source

Duration of post-rebound viral control to <10,000 copies/ml.

open access: yes, 2023
In order to compare the duration of post-rebound control, we compared the proportion of each cohort that maintained post-rebound viral loads below 10,000 copies per ml at different times after ATI.
Christine M. Fennessey (10777108)   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy